IMR Press / RCM / Volume 7 / Issue S4 / pii/1561344070511-665333860

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Impact of Chronic Kidney Disease and Diabetes on Percutaneous Coronary Intervention Outcomes
Show Less
1 The David Geffen School of Medicine at UCLA, Cedars-Sinai Medical Center, Los Angeles, CA
Rev. Cardiovasc. Med. 2006, 7(S4), 38–48;
Published: 20 August 2006
Abnormalities of glucose metabolism and chronic kidney disease (CKD) complicate treatment and outcomes for patients undergoing percutaneous coronary intervention (PCI). Likely causes of the complicating effects of diabetes include hyperglycemia, abnormalities of microvascular perfusion, and a prothrombotic and proinflammatory state. CKD predisposes to atherosclerosis, adds to the mortality and morbidity risk of cardiovascular disease (CVD), and increases risks for patients undergoing PCI. The complexity of the renal dysmetabolic syndrome and its close association with CVD must be taken into account when developing a therapeutic plan for these patients. Clinical data support the use of abciximab for patients with disturbances of glucose metabolism or with CKD who are undergoing PCI. The use of drug-eluting stents reduces the rate of target vessel revascularization and restenosis.
Percutaneous coronary intervention
Chronic kidney disease
Drug-eluting stents
GP IIb/IIIa inhibitors
Back to top